RxDoctor Payments Data

Jesus Bucardo, MD

Psychiatry · Hemet, CANPI 1861581993

Payments from drug & device makers

$24,909in general payments, 2019–2025

Across 154 payments — averaging $161.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$22K
  • Neurocrine Biosciences, Inc.$369
  • Alkermes, Inc.$365
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$347
  • Teva Pharmaceuticals USA, Inc.$298
  • Otsuka America Pharmaceutical, Inc.$271
  • plus $987 from 8 others

What the payments were for

  • Speaking & faculty fees$21,04084%
  • Travel & lodging$5632%
  • Food & beverage$3,30513%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,909 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$4,981
Medicare patients
18
Services billed
55

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate27$78,729
Doxepin Hcl11$2,259
Paliperidone ErPaliperidone13$1,134
Atomoxetine Hcl13$970
Quetiapine Fumarate53$727
Divalproex Sodium ErDivalproex Sodium24$692
Buspirone Hcl36$644
Olanzapine54$564
Gabapentin33$424
Aripiprazole25$378
Bupropion XlBupropion Hcl30$331
Duloxetine Hcl18$320
Trazodone Hcl22$181
Fluoxetine Hcl15$171
Sertraline Hcl34$169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$155$78,72927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Hemet

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →